

UC San Diego

UC San Diego Previously Published Works

Title

Recommendations for clinical management of excessive daytime sleepiness in obstructive sleep apnoea – A Delphi consensus study

Permalink

<https://escholarship.org/uc/item/7p4544zk>

Authors

Steier, Joerg S

Bogan, Richard K

Cano-Pumarega, Irene M

et al.

Publication Date

2023-12-01

DOI

10.1016/j.sleep.2023.10.001

Peer reviewed



Published in final edited form as:

Sleep Med. 2023 December ; 112: 104–115. doi:10.1016/j.sleep.2023.10.001.

Recommendations for clinical management of excessive daytime sleepiness in obstructive sleep apnoea – A Delphi consensus study

Joerg S. Steier^{a,*},¹, Richard K. Bogan^b, Irene M. Cano-Pumarega^c, John A. Fleetham^d, Giuseppe Insalaco^e, Chitra Lal^f, Jean-Louis Pépin^g, Winfried J. Randerath^h, Susan Redlineⁱ, Atul Malhotra^j,¹

^aCentre for Human and Applied Physiological Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

^bMedical University of South Carolina, Charleston, SC, USA

^cSleep Unit, Respiratory Department, Ramón y Cajal University Hospital, IRYCIS, CIBERES, Madrid, Spain

^dDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada

^eInstitute of Translational Pharmacology, Italian National Research Council, Palermo, Italy

^fPulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, College of Medicine, Charleston, SC, USA

^gGrenoble Alpes University, INSERM, University Hospital Grenoble Alpes, HP2, Grenoble, France

^hInstitute of Pneumology at the University of Cologne, Bethanien Hospital, Clinic for Pneumology and Allergology, Centre of Sleep Medicine and Respiratory Care, Solingen, Germany

ⁱBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

^jUniversity of California, San Diego Health, La Jolla, CA, USA

Abstract

Study objective: Excessive daytime sleepiness is common with obstructive sleep apnoea and can persist despite efforts to optimise primary airway therapy. The literature lacks recommendations regarding differential diagnosis and management of excessive daytime sleepiness in obstructive sleep apnoea. This study sought to develop expert consensus statements to bridge the gap between existing literature/guidelines and clinical practice.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

*Corresponding author. School of Medicine, King's College London, St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, United Kingdom. joerg.steier@kcl.ac.uk (J.S. Steier).

¹Study Co-Chairs.

Author contributions

All authors contributed equally to the manuscript, including conceptualisation, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualisation, and writing (original draft, review, and editing).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.sleep.2023.10.001>.

Methods: A panel of 10 international experts was convened to undertake a modified Delphi process. Statements were developed based on available evidence identified through a scoping literature review, and expert opinion. Consensus was achieved through 3 rounds of iterative, blinded survey voting and revision to statements until a predetermined level of agreement was met (80 % voting “strongly agree” or “agree with reservation”).

Results: Consensus was achieved for 32 final statements. The panel agreed excessive daytime sleepiness is a patient-reported symptom. The importance of subjective/objective evaluation of excessive daytime sleepiness in the initial evaluation and serial management of obstructive sleep apnoea was recognised. The differential diagnosis of residual excessive daytime sleepiness in obstructive sleep apnoea was discussed. Optimizing airway therapy (eg, troubleshooting issues affecting effectiveness) was addressed. The panel recognised occurrence of residual excessive daytime sleepiness in obstructive sleep apnoea despite optimal airway therapy and the need to evaluate patients for underlying causes.

Conclusions: Excessive daytime sleepiness in patients with obstructive sleep apnoea is a public health issue requiring increased awareness, recognition, and attention. Implementation of these statements may improve patient care, long-term management, and clinical outcomes in patients with obstructive sleep apnoea.

Keywords

Sleep apnoea syndromes; Practice guideline; Expert testimony

1. Introduction

Recent estimates suggest that nearly one billion adults worldwide have obstructive sleep apnoea (OSA) [1]. Excessive daytime sleepiness (EDS) is the cardinal symptom of OSA [2]. Some studies estimate that 55%–80% of patients with OSA report EDS prior to initiating therapy [3–5], although this may vary depending on the setting and definition [6]. EDS persists in some patients despite normalisation of breathing, oxygenation, and sleep quality when treated with primary OSA therapy, such as continuous positive airway pressure (CPAP) [7,8]. Population-based studies have estimated that between 10% and 28% of patients treated with CPAP continue to experience residual EDS, even when other potential causes of sleepiness (eg, depression, other sleep disorders, medications, comorbidities, and inadequate sleep duration) are controlled [5,9,10]. Recent publications have provided general reviews on EDS in OSA [11,12]; however, there remains a need for consensus in practical guidance on the differential diagnosis and management of EDS in patients with OSA.

The Delphi method is a well-established process for achieving consensus from multiple stakeholders that has been used in healthcare for many purposes [13,14]. It is often employed as a means of eliciting expert opinion on topics for which there is an absence of definitive evidence to guide decisions. Experts in the field participate in rounds of anonymous, iterative survey voting, during which statements/guidelines are voted on and revised accordingly until consensus is achieved [13,14]. In a conventional Delphi method, the survey process is conducted electronically [14].

The current study was designed to address key questions and controversies related to the differential diagnosis and management of EDS in patients with OSA. A Delphi approach was used to develop a set of expert consensus statements to bridge the gap between existing literature/guidelines and real-world practice by providing practical guidance necessary to support clinical decision-making.

2. Methods

2.1. Participants

The Delphi panel included ten international experts in sleep and respiratory medicine from North America and Europe. Two panellists served as co-chairs (J.S. and A.M.) and eight served as section leads (R. B., I.C.-P., J.F., G.I., C.L., J.-L.P., W.R., S.R.). Panellists were invited by the co-chairs based on expertise within the field, diversity in demographics and geography, and background in respiratory and sleep disorders extending beyond sleep apnoea, as well as experience in conducting clinical trials, including those involving pharmacotherapy. Panellists included experts who were clinically active at tertiary referral centres with academic input. Per the protocol, invited panellists who were unable to commit to all rounds of the Delphi process were to be excluded; all invited panellists were included in this study. The study protocol was registered through King's College London via the study co-chair, J.S. Jazz Pharmaceuticals financially sponsored this study. Financial support for this manuscript was provided by Jazz Pharmaceuticals and Axsome Therapeutics. The co-chairs and faculty panel led all steps involved in the planning, evidence review, survey process, and the statement development, which were conducted independently of the industry sponsor.

2.2. Modified Delphi process

This study utilised a modified Delphi method, which differs from a conventional Delphi method such that part of the survey process (eg, final voting) is conducted during a live meeting [14]. The modified Delphi process involved two parts: scoping literature review and survey voting (Supplementary Fig. 1). Co-chairs developed questions related to the differential diagnosis and management of EDS in OSA, which were grouped into four topics (two section leads [one from North America and one from Europe] per topic) (Supplementary Table 1). These questions were used to guide the literature review and generation of statements. The protocol was registered on [ClinicalTrials.gov \(NCT05055271\)](https://clinicaltrials.gov/ct2/show/study/NCT05055271).

2.2.1. Scoping literature review—To ensure the initial statements were guided by existing evidence, a scoping literature review (English language, no limitation on year) was conducted by the study coordinator under the direction of section leads (who determined search parameters, queries, and selection criteria) (see Supplementary Tables 2 and 3 in the online data supplement). Section leads developed initial statements that reflected available evidence and their expert opinion based on experience in/knowledge of the clinical management of EDS in OSA.

2.2.2. Survey voting—An anonymous online survey was developed (compiled by the study coordinator and administered via SurveyMonkey [Momentive, San Mateo, CA]) to determine the panel's level of agreement with the initial statements. The survey was administered to the full panel for each round of remote voting. The first 2 rounds of voting were conducted remotely, while the final round was conducted at a live virtual meeting. All votes and responses for all rounds of voting (remote and live/virtual) were blinded to all panellists. Level of agreement was rated on a five-point Likert scale: strongly agree (A+), agree with reservation (A), undecided (U), disagree (D), or strongly disagree (D+). The survey also included a field for open-ended feedback.

Upon receipt of the first round of responses, section leads revised the statements to achieve further agreement within the panel. At the discretion of the section leads, statements could be regrouped, combined, and/or new statements could be generated to address the feedback. Updated statements were compiled into a new survey and redistributed for a second round of remote voting and subsequent revisions.

Final round of voting was conducted at a two-day live virtual meeting (hosted on Zoom [San Jose, CA]; moderated by co-chairs) to allow the panel to discuss the rationale for the statements, how the statements had evolved, and any remaining reservations for each statement. Statements were further revised at the live meeting based on the discussion, and consensus was determined via anonymous voting (Poll Everywhere, San Francisco, CA). Additional voting and revision continued until consensus was achieved or the statement was removed.

The primary outcome measure was the level of agreement from the panel for all statements. Consensus was predefined as 80% of the panel rating a statement A+ or A.

3. Results

3.1. Rationale for recommendations

The recommendation statements were based on the Delphi consensus process, supported by existing data from selected literature (see Supplementary Tables 4–12 in the online data supplement) and guided by expert opinion based on experience and knowledge of the clinical management of EDS in OSA. All panellists participated in all review rounds.

3.2. Summary of key evidence and recommendations

The panel's agreement on the statements gradually increased across review rounds as the statements were revised based on iterative survey voting and feedback from each member (Supplementary Fig. 2). At the completion of final voting, consensus was achieved for 32 final statements.

3.2.1. Topic 1: how to define and evaluate EDS—Consensus was achieved for all final statements for Topic 1 (Table 1). EDS is defined by difficulty maintaining alertness during the wake periods of a 24-h sleep-wake cycle. Given the prevalence and importance of EDS in the management of patients with OSA, the panel recommended that EDS be assessed during the initial evaluation of OSA and serially over time (at six weeks to

three months following initiation of therapeutic intervention). Thereafter, patients should be reassessed using an appropriate and validated instrument on at least an annual basis to ensure optimal management. Various instruments for assessing EDS were identified, including questionnaires (eg, the Epworth Sleepiness Scale [ESS]) and objective tests (eg, Multiple Sleep Latency Test [MSLT], Maintenance of Wakefulness Test [MWT]; Table 2). Although one specific instrument was not recommended over another, ESS is the most commonly used questionnaire to assess EDS, with changes of two to three points or a 25% reduction from baseline in ESS score indicating a minimum clinically important difference [15–17]. The ESS is, however, limited by its poor predictive value for neurocognitive outcomes and/or motor vehicle accidents and variable test-retest and construct validity, with specific concerns regarding poor psychometric performance in certain populations (eg, older individuals) [18,19]. Recent data have shown that the ESS has good test-retest reliability in controlled clinical trial settings [20] and less reliability when administered across different healthcare settings (eg, between a primary care visit and sleep specialist/secondary care visit) [19,21]. The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment scale (SRI), based on item response theory, has been increasingly used in research settings and holds promise for clinical use, but requires further evaluation for use in management of OSA [22]. The ability of the PROMIS SRI to gauge the severity of sleep-wake problems on a continuum could be particularly useful to enable patients to capture real-time feedback on sleep disturbances and EDS. Most of the alternative questionnaires have not been fully evaluated in terms of their predictive value for important health outcomes (eg, occupational accidents) or psychometric properties (Table 2) [18,19,23–33]. Objective testing of the level of sleepiness with the MSLT or MWT can be useful for quantifying EDS and diagnosing specific conditions (eg, narcolepsy), but these tests require controlled and time-consuming laboratory procedures, precluding widespread and repeated use. The interpretation of any subjective or objective tests for EDS should be undertaken in the appropriate clinical context, with particular attention to the risks of EDS in high-risk individuals (eg, commercial drivers).

3.2.2. Topic 2: how to define and evaluate residual EDS in OSA in patients treated with primary OSA therapy—Consensus was achieved for all final statements for Topic 2 (Table 3). If a patient treated for OSA is suspected of having residual EDS, it is important to first ensure that EDS is not due to suboptimal treatment of OSA, including inadequate adherence to primary OSA therapy. Studies have shown that three months of CPAP therapy can result in resolution of EDS in 66% of patients who are sleepy at baseline [34], and longer durations of treatment (beyond three to six months) may produce further improvement in EDS [5]. Thus, the panel recommended that EDS should be reassessed after three to six months of optimal CPAP therapy, although this window can be individualised. The impact of EDS on alertness, fatigue, cognitive function, and mood should also be recognised.

While the optimal duration of nightly CPAP usage varies, depending on the outcome studied, longer duration of CPAP use per night is beneficial [34]. CPAP usage of more than 6 h per night has been shown to improve several long-term outcomes, including survival [35] and cognition [36], hence the panel recommended that CPAP be used for more than 6 h per

24-h period. In sum, the panel recommended that a diagnosis of residual EDS should only be considered after six months of optimal (6 h/night) CPAP therapy.

If a patient continues to experience EDS after primary OSA therapy has been optimised, the clinician should evaluate for other factors that may be contributing to EDS, such as insufficient sleep, lifestyle factors (eg, diet and exercise), overlapping sleep disorders (eg, narcolepsy and idiopathic hypersomnia), comorbidities (eg, hypothyroidism), concomitant medications, and illicit drug use [37,38]. Long-term management and decision making regarding EDS should include discussion of these factors. Sleep durations of less than 7 h per night can increase the risk of adverse health sequelae, such as cardiovascular disease and diabetes [39]. Sleeping more than 9 h per night is also associated with an increased risk for adverse health outcomes. Hence, the panel recommended that an optimal sleep duration for healthy adults is seven to 9 h per night. This is consistent with recommendations from the National Sleep Foundation and the American Thoracic Society [40,41]. While good sleep hygiene is of paramount importance to ensure optimal nocturnal sleep, short naps can help to achieve an adequate amount of sleep in a 24-h day [42]. Studies have used questionnaires, sleep diaries, and actigraphy to quantify sleep duration; however, the panel noted there are no strong data to recommend one method over another.

3.2.3. Topic 3: how to address specific clinical challenges related to residual EDS in OSA

—Consensus was achieved for all final statements for Topic 3 (Table 4). Some patients with residual EDS in OSA struggle with CPAP therapy because of challenges with achieving high adherence (eg, due to nasal congestion, pressure intolerance, side effects, mask leaks, residual events). Remote monitoring of CPAP downloads can provide valuable information when attempting to address problems related to adherence. In cases related to pressure intolerance, in-laboratory pressure titration can be helpful to optimise pressure settings and, when necessary, provide alternative positive airway pressure modalities (eg, bi-level ventilation). Educational and behavioural strategies (eg, intensive support), technological tools (eg, patient engagement approaches, telemedicine), and pharmacotherapy (eg, drugs to address insomnia or anxiety) are other helpful techniques to facilitate CPAP adherence [43,44]. If a patient is unable or unwilling to continue with CPAP therapy or if CPAP does not achieve adequate results, alternative therapies for OSA should be considered (eg, oral appliance, positional therapy, hypoglossal nerve stimulation, and upper airway or bariatric surgery in selected cases) [45].

If the patient continues to experience EDS after treatment of underlying OSA has been maximized, then additional diagnostic testing (eg, sleep diaries, actigraphy, MSLT) might be helpful in assessing other potential causes of EDS. Diagnostic criteria for idiopathic hypersomnia (IH) includes careful consideration and *exclusion* of other disorders that may cause sleepiness [46]. Considering this definition and from a semantic point of view, concomitant OSA and IH can exist if a patient has previously been diagnosed with IH (at which time a diagnosis of OSA was appropriately excluded), and later develops OSA. If a patient is diagnosed with OSA and then presents with EDS, IH should not be considered as an additional diagnosis.

3.2.4. Topic 4: when and how pharmacological treatment for EDS in OSA should be initiated—Consensus was achieved for all final statements for Topic 4 (Table 5). The panel reinforced the notion that there are some patients who have residual EDS despite adequate primary therapy for OSA. In general, wake-promoting agents should be considered for residual EDS in OSA following optimisation of OSA therapy. However, there may also be some patients who are partially or incompletely treated (such as patients who are poorly adherent with OSA therapy or those in whom the residual apnoea-hypopnoea index [AHI] of <5/hour cannot be achieved). For such patients, pharmacotherapy may be beneficial and could be considered on an individual basis by an experienced sleep clinician. The panel acknowledged that there are limited data to support this recommendation [47,48]; however, this recommendation was prompted by the significant adverse consequences of EDS (such as higher risk of motor vehicle and occupational accidents, poor quality of life, and cognitive impairment) and favourable safety profiles of newer wake-promoting agents. The panel stressed that all efforts to optimise the delivery of treatments aimed to improve airway patency should have been made and other causes of EDS identified and addressed before initiating pharmacotherapy. There are limited data regarding the efficacy and safety of pharmacotherapy in untreated OSA and, therefore, the long-term outcomes of pharmacotherapy in those patients are not conclusively clarified. Individuals who might be amenable to pharmacological intervention need to be carefully evaluated for other underlying causes of EDS and should be closely monitored on treatment.

The majority of studies identified in the literature review (see Supplementary Table 12 in the online data supplement) included patients with EDS despite optimal CPAP use and/or patients who were nonadherent to CPAP therapy despite intensive efforts. The studies excluded patients with concurrent sleep, general medical, neurological, or psychiatric disorders that could cause sleepiness. There is no evidence that wake-promoting drugs influence the underlying pathophysiology of the concomitant sleep disorders. However, short- and long-term use (eg, 12 weeks and 1 year, respectively) of wake-promoting agents have been shown to improve residual EDS in OSA, often accompanied by an improved quality of life [49–67]. Data also show that wake-promoting agents are associated with improvement in validated self-assessment questionnaires and objective outcome measures, such as vigilance tests or electrophysiological tests. Pharmacotherapy may also be beneficial for patients with symptoms at work (eg, drivers) when close monitoring and supervision are provided. The available wake-promoting drugs may differ in terms of adverse effects (eg, changes in blood pressure, changes in heart rate, headache, etc), which might influence the selection of pharmacotherapy for individual patients.

4. Discussion

The synthesis of the literature and the consensus of the Delphi panel generated 32 statements on the definition and evaluation of residual EDS in OSA, how to address specific challenges in its management, and when and how to consider and initiate pharmacotherapy (Table 1, 3–5). EDS is a patient-reported symptom and the importance of subjective and objective evaluation of EDS in the initial evaluation and the serial management of patients was recognised. Optimizing primary OSA airway therapy, including troubleshooting potential issues influencing its efficacy, remains an essential component of the therapeutic approach;

algorithms for symptom management have been reported elsewhere [68]. Clinicians need to consider the differential diagnoses of residual EDS in OSA and the need to evaluate patients for underlying causes that are not related to OSA. Finally, the panel recognised the occurrence of residual EDS in OSA despite optimised primary therapy and recommended the consideration of adjunct pharmacotherapy in its management. The use of wake-promoting agents to treat EDS in specific cases is increasingly recognised based on data from clinical trials, although there remains a need for further long-term data on safety and efficacy [52].

There were several limitations of this Delphi consensus. Because of the limitations of the published evidence, some of the recommendations provided by the panel extend beyond the existing literature and are also based on expert opinion from clinical experience, which must be corroborated by future research. In addition, the number of panellists was relatively small and only comprised experts from North America and Europe; thus geographic representation was limited to these regions and potential variations in clinical management that may be applicable to other areas of the world may not be accounted for in these recommendations. Further, the sociocultural context of EDS was discussed based on the available literature, which is limited by the lack of data for large portions of the world's population. Prior to submission, a respiratory research and patient advocate reviewed the manuscript and statements; however, direct insight from patients with OSA was not included as part of this study. Additionally, a scoping review, rather than a traditional systematic review, was conducted on English-language publications only, although the authors were not aware of major overlooked publications with validated questionnaires from other languages. Of note, the final recommendation statements have not yet been validated by a larger group of healthcare providers. Future work is needed to assess the feasibility of implementing these guidelines in various clinical practice settings.

5. Conclusions

There was general agreement among the Delphi panel that residual EDS in OSA is a major public health problem that requires increased awareness, recognition, and attention. The tools available for evaluating EDS are limited and need to be interpreted in the appropriate clinical context. Residual EDS should be addressed and pharmacological intervention considered once CPAP or other primary therapy for OSA has been optimised. Encouraging engagement and support from family and friends may help facilitate patient adherence with primary treatment, thereby improving management. The panel also recommended that in selected patients with partially treated or incompletely treated OSA, pharmacotherapy may be beneficial and could be considered on an individual basis and prescribed by an experienced sleep clinician with close clinical follow-up. Implementation of the consensus recommendations will help to improve patient care, long-term management, and clinical outcomes of patients with OSA.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Under the direction of the authors, medical writing and editorial assistance were provided by Peloton Advantage, LLC, an OPEN Health company, and were funded by Axsome Therapeutics and Jazz Pharmaceuticals. However, the academic co-chairs (Steier, Malhotra) produced the first and subsequently revised drafts of the manuscript. The manuscript was also reviewed by patient advocate and respiratory research advocate, Teresa Barnes.

Funding

This study was supported by Jazz Pharmaceuticals. The development of the manuscript was funded by Axsome Therapeutics and Jazz Pharmaceuticals.

Role of the sponsor

The study protocol was registered through King's College London via the study co-chair, J.S. The Delphi consensus was coordinated by a publication planning company, Peloton Advantage, an Open Health company, Parsippany, NJ (study coordinator) and was funded by Jazz Pharmaceuticals, Palo Alto, CA. Financial support for this manuscript was provided by Jazz Pharmaceuticals and Axsome Therapeutics. The consensus concept was initiated by Jazz Pharmaceuticals and is now supported by Axsome Therapeutics in collaboration with Peloton Advantage, the co-chairs, and the panel. The statements were developed independently of the industry financial sponsors (ie, the financial sponsors did not participate in the development of the statements or in the meetings/discussions of the Delphi process). The academic authors produced the first draft of the manuscript and were not precluded from accessing data in the study; they accept responsibility to submit for publication.

Declaration of competing interest

J. Steier has received consultancy fees from Jazz Pharmaceuticals. R. Bogan is a shareholder of WaterMark Medical and Healthy Humming, LLC; serves on the board of directors for WaterMark Medical; receives consultancy fees from Jazz Pharmaceuticals, Harmony Biosciences, Avadel Pharmaceuticals, Takeda, and Oventus; performs industry-funded research for Avadel, Axsome, Bresotec, Bayer, Idorsia, Suven, Jazz, Balance, NLS, Vanda, Merck, Eisai, Philips, Fresca, Takeda, Liva Nova, Roche, Sanofi, Sommetrics, and Noctrix; and serves on the speakers bureau for Jazz, Eisai, and Harmony. I. Cano-Pumarega has received consultancy fees from Jazz Pharmaceuticals and Bioprojet, as well as fees for speaking activities from Jazz Pharmaceuticals. J. Fleetham has received consultancy fees and fees for speaking activities from Jazz Pharmaceuticals. G. Insalaco has received consultancy fees and fees for speaking activities from Jazz Pharmaceuticals and Bioprojet. C. Lal has received consultancy fees from Jazz Pharmaceuticals and Chest/ GSK. J.-L. Pepin has received lecture fees or conference traveling grants from Resmed, Perimetre, Philips, Fisher and Paykel, AstraZeneca, Jazz Pharmaceuticals, Agiradom, and Bioprojet, and has received unrestricted research funding from ResMed, Philips, GlaxoSmithKline, Bioprojet, Fondation de la Recherche Medicale (Foundation for Medical Research), Direction de la Recherche Clinique du CHU de Grenoble (Research Branch Clinic CHU de Grenoble), and fond de dotation "Agir pour les Maladies Chroniques" (endowment fund "Acting for Chronic Diseases"). W. Randerath is a member of the advisory board and receives consultancy fees, personal fees, and travel grants from Jazz Pharmaceuticals and Bioprojet and (outside this topic) from Philips Respironics (ended 2021) and Desitin (ended 2020). S. Redline received grants from Jazz and NIH and consultancy fees from Jazz, Eli Lilly, Apnimed Inc, and Eisai Inc. A. Malhotra receives funding from NIH; receives income related to medical education from Livanova, Jazz, Equillum, and Corvus; and reports that ResMed provided a philanthropic donation to UC San Diego.

Abbreviations:

AHI	apnoea-hypopnoea index
CPAP	continuous positive airway pressure
EDS	excessive daytime sleepiness
ESS	Epworth Sleepiness Scale
IH	idiopathic hypersomnia
MWT	Maintenance of Wakefulness Test
MSLT	Multiple Sleep Latency Test

OSA	obstructive sleep apnoea
PROMIS SRI	Patient-Reported Outcomes Measurement Information System Sleep Related Impairment scale

References

- [1]. Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med* 2019;7(8):687–98. [PubMed: 31300334]
- [2]. American Academy of Sleep Medicine. *International Classification of Sleep Disorders*. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
- [3]. Bailly S, Destors M, Grillet Y, et al. Obstructive sleep apnea: a cluster analysis at time of diagnosis. *PLoS One* 2016;11(6):e0157318.
- [4]. Koutsourelakis I, Perraki E, Economou NT, et al. Predictors of residual sleepiness in adequately treated obstructive sleep apnoea patients. *Eur Respir J* 2009;34(3): 687–93. [PubMed: 19357151]
- [5]. Bonsignore MR, Pepin JL, Cibella F, et al. Excessive daytime sleepiness in obstructive sleep apnea patients treated with continuous positive airway pressure: data from the European sleep apnea database. *Front Neurol* 2021;12:690008.
- [6]. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993;328(17): 1230–5. [PubMed: 8464434]
- [7]. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med* 2019;15(2):335–43. [PubMed: 30736887]
- [8]. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med* 2009;5(3):263–76. [PubMed: 19960649]
- [9]. Gasa M, Tamisier R, Launois SH, et al. Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure. *J Sleep Res* 2013;22(4):389–97. [PubMed: 23409736]
- [10]. Pepin JL, Viot-Blanc V, Escourrou P, et al. Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. *Eur Respir J* 2009;33(5):1062–7. [PubMed: 19407048]
- [11]. He K, Kapur VK. Sleep-disordered breathing and excessive daytime sleepiness. *Sleep Med Clin* 2017;12(3):369–82. [PubMed: 28778235]
- [12]. Javaheri S, Javaheri S. Update on persistent excessive daytime sleepiness in OSA. *Chest* 2020;158(2):776–86. [PubMed: 32147246]
- [13]. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. *PLoS Med* 2011;8(1):e1000393.
- [14]. de Villiers MR, de Villiers PJ, Kent AP. The Delphi technique in health sciences education research. *Med Teach* 2005;27(7):639–43. [PubMed: 16332558]
- [15]. Leher P. Epworth sleepiness scale ESS: determination of a minimum clinically relevant difference [abstract]. *Sleep Med* 2017;40(suppl 1):e186–7.
- [16]. Patel S, Kon SSC, Nolan CM, et al. The Epworth Sleepiness Scale: minimum clinically important difference in obstructive sleep apnea. *Am J Respir Crit Care Med* 2018;197(7):961–3. [PubMed: 28961021]
- [17]. Scrima L, Emsellem HA, Becker PM, et al. Identifying clinically important difference on the Epworth Sleepiness Scale: results from a narcolepsy clinical trial of JZP-110. *Sleep Med* 2017;38:108–12. [PubMed: 29031743]
- [18]. Kendzerska TB, Smith PM, Brignardello-Petersen R, Leung RS, Tomlinson GA. Evaluation of the measurement properties of the Epworth Sleepiness Scale: a systematic review. *Sleep Med Rev* 2014;18(4):321–31. [PubMed: 24135493]

- [19]. Campbell AJ, Neill AM, Scott DAR. Clinical reproducibility of the Epworth Sleepiness Scale for patients with suspected sleep apnea. *J Clin Sleep Med* 2018;14 (5):791–5. [PubMed: 29734985]
- [20]. Rosenberg R, Babson K, Menno D, et al. Test-retest reliability of the Epworth Sleepiness Scale in clinical trial settings. *J Sleep Res* 2022;31(2):e13476.
- [21]. Taylor E, Zeng I, O’Dochartaigh C. The reliability of the Epworth Sleepiness Score in a sleep clinic population. *J Sleep Res* 2019;28(2):e12687.
- [22]. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med* 2011;10(1):6–24. [PubMed: 22250775]
- [23]. Arand D, Bonnet M, Hurwitz T, Mitler M, Rosa R, Sangal RB. The clinical use of the MSLT and MWT. *Sleep* 2005;28(1):123–44. [PubMed: 15700728]
- [24]. Grewe FA, Roeder M, Bradicich M, et al. Low repeatability of Epworth Sleepiness Scale after short intervals in a sleep clinic population. *J Clin Sleep Med* 2020;16(5): 757–64. [PubMed: 32039756]
- [25]. Hunasikatti M. Low repeatability of the Epworth Sleepiness Scale and the need to redefine the minimal clinically important difference. *J Clin Sleep Med* 2020;16 (10):1827. [PubMed: 33063661]
- [26]. Buysse DJ, Yu L, Moul DE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. *Sleep* 2010;33(6):781–92. [PubMed: 20550019]
- [27]. Jensen RE, King-Kallimanis BL, Sexton E, et al. Measurement properties of PROMIS sleep disturbance short forms in a large, ethnically diverse cancer cohort. *Psychol Test Assess Model* 2016;58(2):353–70.
- [28]. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. *Sleep* 2005;28 (1):113–21. [PubMed: 15700727]
- [29]. Shrestha SK, Shrestha S, Rajkarnikar R, et al. Comparing four standard sleep questionnaires to polysomnography to predict possibility of obstructive sleep apnea and its severity. *J Adv Intern Med* 2021;10(1):33–7.
- [30]. Chasens ER, Ratcliffe SJ, Weaver TE. Development of the FOSQ-10: a short version of the functional outcomes of sleep questionnaire. *Sleep* 2009;32(7):915–9. [PubMed: 19639754]
- [31]. Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. *Sleep* 1997;20(10):835–43. [PubMed: 9415942]
- [32]. Billings ME, Rosen CL, Auckley D, et al. Psychometric performance and responsiveness of the functional outcomes of sleep questionnaire and sleep apnea quality of life instrument in a randomized trial: the HomePAP study. *Sleep* 2014;37 (12):2017–24. [PubMed: 25325491]
- [33]. Lacasse Y, Godbout C, Se iès F. Independent validation of the sleep apnoea quality of life index. *Thorax* 2002;57(6):483–8. [PubMed: 12037222]
- [34]. Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. *Sleep* 2007;30(6): 711–9. [PubMed: 17580592]
- [35]. Campos-Rodriguez F, Peña-Griñan N, Reyes-Nuñez N, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. *Chest* 2005;128(2):624–33. [PubMed: 16100147]
- [36]. Zimmerman ME, Aloia MS. A review of neuroimaging in obstructive sleep apnea. *J Clin Sleep Med* 2006;2(4):461–71. [PubMed: 17557478]
- [37]. Lal C, Weaver TE, Bae CJ, Strohl KP. Excessive daytime sleepiness in obstructive sleep apnea: mechanisms and clinical management. *Ann Am Thorac Soc* 2021;18 (5):757–68. [PubMed: 33621163]
- [38]. Rosenberg R, Schweitzer PK, Steier J, Pepin JL. Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management. *Postgrad Med* 2021;133(7):772–83. [PubMed: 34292843]
- [39]. Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. *Sleep* 2015;38(6):843–4. [PubMed: 26039963]

- [40]. Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation's updated sleep duration recommendations: final report. *Sleep health* 2015;1(4):233–43. [PubMed: 29073398]
- [41]. Mukherjee S, Patel SR, Kales SN, et al. An official American thoracic society statement: the importance of healthy sleep. Recommendations and future priorities. *Am J Respir Crit Care Med* 2015;191(12):1450–8. [PubMed: 26075423]
- [42]. Caldwell JA, Caldwell JL, Thompson LA, Lieberman HR. Fatigue and its management in the workplace. *Neurosci Biobehav Rev* 2019;96:272–89. [PubMed: 30391406]
- [43]. Askland K, Wright L, Wozniak DR, Emmanuel T, Caston J, Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. *Cochrane Database Syst Rev* 2020;4(4):Cd007736.
- [44]. Wang D, Tang Y, Chen Y, et al. The effect of non-benzodiazepine sedative hypnotics on CPAP adherence in patients with OSA: a systematic review and meta-analysis. *Sleep* 2021;44(8).
- [45]. Randerath W, Verbraecken J, de Raaff CAL, et al. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. *Eur Respir Rev* 2021;30(162).
- [46]. American Academy of Sleep Medicine. Idiopathic Hypersomnia. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
- [47]. Chapman JL, Kempler L, Chang CL, et al. Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. *Thorax* 2014;69(3): 274–9. [PubMed: 24287166]
- [48]. Malhotra RK. Pro-con debate: use of wake-promoting agents for the treatment of daytime fatigue in OSA patients with curtailed CPAP use (less than 6 h). *Current sleep medicine reports* 2020;6(3):184–8.
- [49]. Chapman JL, Cayanan EA, Hoyos CM, et al. Does armodafinil improve driving task performance and weight loss in sleep apnea? A randomized trial. *Am J Respir Crit Care Med* 2018;198(7):941–50. [PubMed: 29775087]
- [50]. Kay GG, Feldman N. Effects of armodafinil on simulated driving and self-report measures in obstructive sleep apnea patients prior to treatment with continuous positive airway pressure. *J Clin Sleep Med* 2013;9(5):445–54. [PubMed: 23674935]
- [51]. Black JE, Hull SG, Tiller J, Yang R, Harsh JR. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. *J Clin Sleep Med* 2010;6(5):458–66. [PubMed: 20957846]
- [52]. Williams SC, Marshall NS, Kennerson M, Rogers NL, Liu PY, Grunstein RR. Modafinil effects during acute continuous positive airway pressure withdrawal: a randomized crossover double-blind placebo-controlled trial. *Am J Respir Crit Care Med* 2010;181(8):825–31. [PubMed: 20056901]
- [53]. Bittencourt LR, Lucchesi LM, Rueda AD, et al. Placebo and modafinil effect on sleepiness in obstructive sleep apnea. *Prog Neuro-Psychopharmacol Biol Psychiatry* 2008;32(2):552–9.
- [54]. Williams SC, Rogers NL, Marshall NS, Leung S, Stamer GA, Grunstein RR. The effect of modafinil following acute CPAP withdrawal: a preliminary study. *Sleep Breath* 2008;12(4):359–64. [PubMed: 18311493]
- [55]. Hirshkowitz M, Black JE, Wesnes K, Niebler G, Arora S, Roth T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/ hypopnea syndrome. *Respir Med* 2007;101(3):616–27. [PubMed: 16908126]
- [56]. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. *Clin Therapeut* 2006;28(5):689–706.
- [57]. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/ hypopnea syndrome. *Sleep* 2005;28(4):464–71. [PubMed: 16171291]
- [58]. Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. *Sleep Med* 2003;4(5):393–402. [PubMed: 14592280]

- [59]. Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. *Am J Respir Crit Care Med* 2001;163(4):918–23. [PubMed: 11282766]
- [60]. Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. *Am J Respir Crit Care Med* 2001;164 (9):1675–81. [PubMed: 11719309]
- [61]. Pépin JL, Georgiev O, Tiholov R, et al. Pitolisant for residual excessive daytime sleepiness in OSA patients adhering to CPAP: a randomized trial. *Chest* 2021;159 (4):1598–609. [PubMed: 33121980]
- [62]. Schweitzer PK, Mayer G, Rosenberg R, et al. Randomized controlled trial of solriamfetol for excessive daytime sleepiness in obstructive sleep apnea: an analysis of subgroups adherent or nonadherent to obstructive sleep apnea treatment. *Chest* 2021;160(1):307–18. [PubMed: 33631141]
- [63]. Schweitzer PK, Strohl KP, Mayer G, et al. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. *J Clin Sleep Med* 2021;17(4):659–68. [PubMed: 33179591]
- [64]. Dauvilliers Y, Verbraecken J, Partinen M, et al. Pitolisant for daytime sleepiness in obstructive sleep apnea patients refusing CPAP: a randomized trial. *Am J Respir Crit Care Med* 2020;201(9):1135–45. [PubMed: 31917607]
- [65]. Malhotra A, Shapiro C, Pepin JL, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. *Sleep* 2020; 43(2):zsz220.
- [66]. Weaver TE, Drake CL, Benes H, et al. Effects of solriamfetol on quality of life measures from a 12-week phase 3 randomized trial. *Ann Am Thorac Soc* 2020;17 (8):998–1007. [PubMed: 32353246]
- [67]. Strollo PJ Jr, Hedner J, Collop N, et al. Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study. *Chest* 2019; 155(2):364–74. [PubMed: 30471270]
- [68]. Craig S, Pépin JL, Randerath W, et al. Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view. *Eur Respir Rev* 2022;31(164):210230.

Table 1Level of agreement/disagreement with each statement during each round:^a How to define and evaluate EDS.

Statement Number	Statement ^b	Response	Response Rate (%)		
			Round 1	Round 2	Round 3
1	Sleepiness should be assessed at baseline and then re-assessed within 6 weeks to 3 months, and then annually thereafter, following initiation of therapy for OSA. In well-treated patients without clinical need, less frequent assessments may also be acceptable. More frequent assessments may be needed in cases with patient-initiated contact, severity and clinical impact of EDS, reasons for concern, changes in health status (eg, weight gain), or other considerations (eg, high-risk occupations, such as professional drivers or those operating machinery)	Strongly agree	60	100	100
		Agree with reservation	40	0	0
		Undecided	0	0	0
		Disagree Strongly	0	0	0
		disagree	0	0	0
2	Sleepiness and EDS are patient-reported symptoms that can be defined by the inability to perform/master tasks that require vigilance or to stay awake against intention. Assessment of the symptom in a real-world population requires the use of a careful history, supplemented by standardized questionnaires that quantify the degree of EDS and related impairment. In the context of evaluating the spectrum of sleep disorders, the assessment may be complemented by a clinician-guided choice of objective markers (eg, Maintenance of Wakefulness Test, Multiple Sleep Latency Test, Psychomotor Vigilance Task)	Strongly agree	80	80	100
		Agree with reservation	20	20	0
		Undecided	0	0	0
		Disagree Strongly	0	0	0
		disagree	0	0	0
3	The Epworth Sleepiness Scale (ESS) is the most commonly used questionnaire to assess EDS in adult patients with OSA within a clinical setting; however, alternative questionnaires (eg, Patient Reported Outcomes Measurement System Sleep-Related Impairment [PROMIS SRI]) may be appropriate. Additional evaluation using objective measures may be more appropriate for certain patient populations (eg, where questionnaire items may be unsuitable for different cultures or populations) and in those where there are discrepancies between questionnaire-based assessments and clinical history	Strongly agree	50	60	100
		Agree with reservation	50	30	0
		Undecided	0	0	0
		Disagree Strongly	0	10	0
		disagree	0	0	0
4	Clinicians are encouraged to understand the limitations associated with each instrument and use psychometric characteristics to choose the most appropriate tool for a specific population and context. Table 2 lists instruments used to assess sleepiness and related outcomes in patients with OSA and their psychometric properties, including sensitivity, specificity, reliability (internal consistency), repeatability (test-re-test reliability), construct validity, and clinical relevance.	Strongly agree	80	90	100
		Agree with reservation	20	0	0
		Undecided	0	10	0
		Disagree Strongly	0	0	0
		disagree	0	0	0
5	Future research is needed to validate and generate additional psychometric data on promising instruments to measure sleepiness and other patient-reported outcomes, with particular attention to certain populations (eg, depending on age, sociocultural background, language, special needs, and other factors).	Strongly agree	80	90	100
		Agree with reservation	20	10	0
		Undecided	0	0	0
		Disagree Strongly	0	0	0
		disagree	0	0	0
6	Although EDS occurs across a continuum, cut-off values are useful for defining clinically important levels of EDS (Table 2) but should not be used in isolation. These values can be used in the appropriate clinical context to identify patients who may benefit from additional intervention.	Strongly agree	50	80	100
		Agree with reservation	50	10	0
		Undecided	0	0	0
		Disagree Strongly	0	10	0
		disagree	0	0	0
7	Clinicians should consider objective assessments in appropriate clinical contexts when caring for patients with EDS where results may change management (eg, discordance between patient report and clinician or partner perception).	Strongly agree	80	90	100
		Agree with reservation	10	10	0
		Undecided	10	0	0
		Disagree Strongly	0	0	0
		disagree	0	0	0

^aConsensus was considered to be achieved if 80% of respondents agreed or agreed with reservation.

^bFinal statements shown. CPAP = continuous positive airway pressure, EDS = excessive daytime sleepiness, ESS = Epworth Sleepiness Scale, IH = idiopathic hypersomnia, OA = oral appliance, OSA = obstructive sleep apnoea, PAP = positive airway pressure, PROMIS SRI=Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment, QoL = quality of life.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

Instruments used to assess sleepiness and related outcomes in patients with OSA and their psychometric properties.

Tool	Sensitivity	Specificity	Reliability (Internal Consistency)	Repeatability (Test-retest Reliability)	Construct Validity	MCID Threshold
Epworth Sleepiness Scale (ESS)	93-5% (for cutoff score >10) [23]	100% (for cutoff score >10) [23]	Cronbach's $\alpha = 0.70-0.88$ (acceptable) [18] Not unidimensional [18]	Recent data have questioned the short-term and long-term reliability of the ESS with insufficient test-retest reliability even within the same day, suggesting situational sleepiness (ie, time of test administration) may influence ESS scores [19,24]. Studies have found the ESS to have good test-retest reliability in controlled clinical trials settings and less reliability when administered across different primary/secondary care settings (eg, between PCP and sleep specialist visit) [19, 24]	Moderate association between ESS and MWT [18] Weak association between ESS and MSLT [18] ESS shows statistical, but perhaps not clinically meaningful, differences across groups with known differences in EDS [18]	Decrease of 2-3 points, although some suggest a decrease of 5-6 points be considered as the MCID for clinical decision-making or when assessing treatment effects to account for low reliability [24,25]
Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment (PROMIS SRI)	NA ^a	NA ^a	Cronbach's $\alpha = 0.96$ (high) [26]	NA ^a	PROMIS shows statistical differences between individuals with and without a sleep disorder, as well as between those with treated and untreated sleep disorders [26]	2 points ^b [27]
Multiple Sleep Latency Test (MSLT)	80-9% (for cutoff <5 min) [23] 94-5% (for cutoff <8 min) ^c [23] Low sensitivity for severe levels of EDS	89-8% (for cutoff <5 min) [23] 73-3% (for cutoff <8 min) ^c [23]	Can be sensitive to a basement effect, as well as affected by activity prior to testing, caffeine use, age, and instructions [23]	High test-retest reliability in healthy individuals [23,28] Excellent intra- and interrater reliability in sleep disorder populations, although variable depending on sleep disorder (test-retest correlation $r = 0.65$ for insomnia and $r = 0.93$ for narcolepsy) [23,28]	MSLT mean sleep latency is characteristically increased after administration of stimulant medication and reduced after administration of sedating medication [23]	There are no established levels to indicate what magnitude of change is considered clinically important [28]
Maintenance of Wakefulness Test (MWT)	84% (for cutoff <12 min) ^b [23]	98% (for cutoff <12 min) ^c [23]	Can be sensitive to a ceiling effect, as well as affected by activity prior to testing, caffeine use, age, and instructions [23]	NA	MWT mean sleep latency is increased after the administration of wake-promoting medication, ^a stimulants, and CPAP treatment and is reduced after the administration of sedating medication [28]	There are no established levels to indicate what magnitude of change is considered clinically important [28]
Functional Outcomes of Sleep Questionnaire (FOSQ)	AHI 5 = 32.8% [29] AHI 15 = 34.4% [29] AHI 30 = 33.3% [29]	AHI 5 = 66.7% [29] AHI 15 = 77.8% [29] AHI 30 = 67.9% [29] NA	Cronbach's $\alpha = 0.87$ [30]	Test-retest correlation of Total score was $r = 0.90$; test-retest reliability of individual subscales ranges from $r = 0.81$ to $r = 0.90$ [31]	Acceptable as determined by correlation of FOSQ and SAQLI with ESS [32]	Change of 1 SEM [32]

Tool	Sensitivity	Specificity	Reliability (Internal Consistency)	Repeatability (Test-retest Reliability)	Construct Validity	MCID Threshold
Sleep Apnea Quality of Life Index (SAQLI)	May be insensitive to important changes in QoL that patients with OSA experience as a result of therapy [33]	NA	Cronbach's α 0-90 [33]	Test-retest correlation ranges from $r = 0.91$ to $r = 0.94$ [33]	Moderate to high correlation between SAQLI and related measures on related questionnaires (symptoms, daily life activities, social interactions, and emotions on the SF-36, ESS, Beck Depression Inventory, and Symptom Checklist 90) [33]	Change of 1 SEM [32]

AHI = apnoea-hypopnoea index, EDS = excessive daytime sleepiness, ESS = Epworth Sleepiness Scale, FOSQ=Functional Outcomes of Sleep Questionnaire, MCID = minimum clinically important difference, MSLT = Multiple Sleep Latency Test, MWT = Maintenance of Wakefulness Test, NA = not applicable, OSA = obstructive sleep apnoea, PCP = primary care physician, PROMIS SRI=Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment, QoL = quality of life, SAQLI=Sleep Apnea Quality of Life Index, SEM = standard error of mean, SF-36 = 36-Item Short Form Health Survey.

^aNA for adult OSA population.

^bNot a sleep disorder population.

^cIn patients with narcolepsy.

Table 3

Level of agreement/disagreement during each round:^a How to define and evaluate residual EDS in OSA in patients treated with primary OSA therapy.

Statement Number	Statement ^b	Response Rate (%)		
		Round 1	Round 2	Round 3
8	Before diagnosing residual EDS associated with OSA, the patient should use optimal primary airway therapy (eg, CPAP, oral appliance) for 3–6 months, although the clinician should use his/her clinical judgment as longer treatment periods may be necessary to observe improvements in some patients. The clinician should first assess whether OSA treatment is optimised based on clinical assessment, CPAP downloads, and CPAP titration as necessary. If the patient is on CPAP treatment, clinicians should assess for good compliance (used throughout sleep, ideally for at least 6 h per night) and for correct mask fitting with limited leaks should be ensured; if the patient is treated with OA, appropriate adjustment to minimize residual sleep-disordered breathing and a good compliance should be assessed.	40	40	90
		Strongly agree	Agree with reservation	40
		Undecided	Disagree	10
		Strongly disagree		0
				0
				0
				0
9	For optimal treatment of OSA, it is recommended that CPAP is used throughout sleep, ideally for at least 6h per night, although longer durations of use may be needed to observe improvement in some outcomes.	70	90	90
		Strongly agree	Agree with reservation	20
		Undecided	Disagree	10
		Strongly disagree		10
				0
				0
				0
10	Prior to diagnosing residual EDS associated with OSA, other causes should be evaluated, including inadequate sleep duration, drug abuse (eg, tetrahydrocannabinol), comorbidities (eg, depression, hypothyroidism), concomitant medications, and other sleep disorders (eg, idiopathic hypersomnia, narcolepsy). A differential diagnosis can often be made by the primary care physician based on medical history, but referral to a sleep specialist may be warranted for more complex cases.	70	100	90
		Strongly agree	Agree with reservation	30
		Undecided	Disagree	0
		Strongly disagree		0
				0
				0
11	Adequate self-reported sleep duration in adults is optimally 7–9 h per 24-h period, however, there may be a wide range of what is considered normal. Sleep durations 6 h per 24-h period are associated with documented adverse health sequelae, such as impaired immunity, cardiometabolic disorders and increased risk of mortality. Although there is some individual variability, sleep durations greater than 9h per 24-h period, can be associated with adverse health-related sequelae, and may reflect underlying sleep disorders or comorbidities.	70	80	90
		Strongly agree	Agree with reservation	30
		Undecided	Disagree	0
		Strongly disagree		0
				0
				0
				0
12	There is no gold standard for assessment of sleep duration. To establish whether the above criterion for adequate sleep has been met for an individual patient, clinicians may consider assessment of sleep duration using sleep diaries over a 2-week period, actigraphy, or other validated wearable technologies.	90	70	80
		Strongly agree	Agree with reservation	0
		Undecided	Disagree	10
		Strongly disagree		0
				10
				0
				0

Statement Number	Statement ^b	Response Rate (%)		
		Round 1	Round 2	Round 3
13	In patients with EDS and chronic partial sleep deprivation (less than 7 h per 24-h period), it is recommended to encourage healthy sleep and circadian practices and consider short naps as an initial approach to ensure an adequate amount of sleep is obtained over a 24-h period.	60	70	100
		30	20	0
		0	10	0
		10	0	0
		0	0	0
14	Some individuals have residual EDS, even after optimizing primary airway therapy and in the absence of other identified causes, although the mechanisms are unclear.	90	100	100
		10	0	0
		0	0	0
		0	0	0
		0	0	0

^aConsensus was considered to be achieved if 80% of respondents agreed or agreed with reservation.

^bFinal statements shown. CPAP = continuous positive airway pressure, EDS = excessive daytime sleepiness, ESS = Epworth Sleepiness Scale, IH = idiopathic hypersomnia, OA = oral appliance, OSA = obstructive sleep apnoea, PAP = positive airway pressure, PROMIS SRI=Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment, QoL = quality of life.

Table 4

Level of agreement/disagreement with each statement during each round:^a How to address specific clinical challenges related to residual EDS in OSA.

Statement Number	Statement ^b	Response	Response Rate (%)		
			Round 1	Round 2	Round 3
15	In patients with EDS who are intolerant to PAP therapy (or other primary therapies) or have attempted/are attempting therapy, clinicians should identify and attempt to resolve all issues related to therapy intolerance and consider appropriate alternative therapies.	Strongly agree	80	100	100
		Agree with reservation	20	0	0
		Undecided Disagree	0	0	0
		Strongly disagree	0	0	0
			0	0	0
16	Optimizing primary therapy for OSA to improve adherence and efficacy is important and could include educational and behavioral strategies, technological tools (telemedicine), and pharmacological treatments (eg, for insomnia, anxiety).	Strongly agree	70	100	100
		Agree with reservation	20	0	0
		Undecided Disagree	10	0	0
		Strongly disagree	0	0	0
			0	0	0
17	Main strategies to improve adherence are to: a) provide intensive educational support, patient engagement tools, cognitive behavioral therapy, and/or mask desensitization; b) check the mask fit for optimal comfort and leaks; c) address nasal patency; d) identify and treat any side effects, including consideration of a chin strap or humidification; e) assess the correct pressure titration and consider additional PAP modalities; f) assess and treat any comorbid sleep disorders (eg, insomnia) and consider use of sedative-hypnotic treatment during CPAP initiation; g) problem solve any barriers including psychosocial, financial, and/or motivational.	Strongly agree	60	100	100
		Agree with reservation	30	0	0
		Undecided Disagree	0	0	0
		Strongly disagree	10	0	0
			0	0	0
18	For patients who refuse PAP or remain non-adherent despite the previous strategies, clinicians should prioritize lifestyle interventions and consider the use of alternative therapies including oral appliances, positional therapy, surgery (including hypoglossal nerve stimulation, adenotonsillectomy, maxillomandibular osteotomy, bariatric surgery), and/or upper airway neuromuscular intervention.	Strongly agree	60	100	100
		Agree with reservation	40	0	0
		Undecided Disagree	0	0	0
		Strongly disagree	0	0	0
			0	0	0
19	Efforts to treat underlying OSA should be maximized; in sleepy patients who are sub-optimally treated for OSA, clinicians should consider pharmacological alerting therapy for EDS if there is a good risk:benefit ratio.	Strongly agree	60	90	100
		Agree with reservation	30	10	0
		Undecided Disagree	10	0	0
		Strongly disagree	0	0	0
			0	0	0
20	If OSA is being optimally treated and the patient continues to have residual EDS, the clinician should recognize and ensure treatment of any other causes of EDS, including sleep deprivation, psychiatric illness (in particular depression), idiopathic hypersomnia, narcolepsy, circadian rhythm disorders, hypoventilation, neurological diseases, chronic medical conditions (eg, hypothyroidism), concomitant medications, or illicit drug use.	Strongly agree	90	90	100
		Agree with reservation	10	10	0
		Undecided Disagree	0	0	0
		Strongly disagree	0	0	0
			0	0	0
21	If the clinician suspects the cause of EDS is due to an etiology other than OSA, additional diagnostic testing may be required, including a Multiple Sleep Latency Test following a polysomnography on airway therapy (to rule out other disorders of hypersomnolence, such as narcolepsy), actigraphy, or sleep diaries (to rule out insufficient sleep).	Strongly agree	100	90	100
		Agree with reservation	0	10	0
		Undecided Disagree	0	0	0
		Strongly disagree	0	0	0
			0	0	0

Statement Number	Statement ^b	Response	Response Rate (%)		
			Round 1	Round 2	Round 3
22	A patient can have a diagnosis of OSA with comorbid IH if the patient was previously diagnosed with IH (with OSA excluded) and later developed OSA. If a patient with OSA was not previously diagnosed with IH, the persistent EDS should not be considered IH.	Strongly agree	50	90	90
		Agree with reservation	40	10	10
		Undecided	10	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0
23	To distinguish between a diagnosis of EDS due to OSA and OSA with hypersomnia due to other disorders, it is important to take a comprehensive medical history to establish a timeline as to when symptoms occurred.	Strongly agree	90	100	100
		Agree with reservation	10	0	0
		Undecided	0	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0

^aConsensus was considered to be achieved if 80% of respondents agreed or agreed with reservation.

^bFinal statements shown. CPAP = continuous positive airway pressure, EDS = excessive daytime sleepiness, ESS = Epworth Sleepiness Scale, IH = idiopathic hypersomnia, OA = oral appliance, OSA = obstructive sleep apnoea, PAP = positive airway pressure, PROMIS SRI=Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment, QoL = quality of life.

Table 5

Level of agreement/disagreement with each statement during each round:^a When and how pharmacological treatment for EDS in OSA should be initiated.

Statement Number	Statement ^b	Response	Response Rate (%)		
			Round 1	Round 2	Round 3
24	Pharmacological treatment of residual EDS due to OSA should be considered if efficacy of therapy for OSA has been optimised; possible underlying medical, neurologic, psychiatric, and sleep disorders have been addressed to achieve adequate sleep; and there is good risk:benefit ratio with therapy.	Strongly agree	70	100	100
		Agree with reservation	30	0	0
		Undecided	0	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0
25	Pharmacological treatment of residual EDS due to OSA should be considered if EDS substantially reduces quality of life, impairs ability to work or learn, or increases risk of motor vehicle or workplace accidents. It is recognised these agents may improve EDS but do not treat sleep disordered breathing or reduce medical consequences of OSA.	Strongly agree	100	100	100
		Agree with reservation	0	0	0
		Undecided	0	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0
26	In selected cases with EDS, pharmacological treatment may be considered for patients who are not adherent to or could not be treated with primary therapies. However, ongoing clinical efforts to treat OSA adequately are strongly recommended.	Strongly agree	70	80	100
		Agree with reservation	10	20	0
		Undecided	20	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0
27	The selection of wake-promoting drugs should be based on potential efficacy, safety, and risk:benefit ratio of therapy and cardiovascular, central nervous system, and psychiatric comorbidities, as well as accompanying sleep disorders.	Strongly agree	80	100	100
		Agree with reservation	20	0	0
		Undecided	0	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0
28	The use of pharmacological treatment of EDS must not impede the early diagnosis and management of OSA and underlying conditions. Pharmacological treatment of EDS due to OSA may be considered in patients after motor vehicle or workplace accidents or near-accidents	Strongly agree	90	100	100
		Agree with reservation	10	0	0
		Undecided	0	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0
29	Validated patient reported outcome measures (Table 2) facilitate clinical assessment of the presence and severity of EDS, including the potential impact of EDS on QOL as well as safety. These measures supplement clinical assessment of severity and change with OSA management.	Strongly agree	80	80	100
		Agree with reservation	20	20	0
		Undecided	0	0	0
		Disagree	0	0	0
		Strongly disagree	0	0	0
30	In selected cases, objective measurements of EDS due to OSA may be performed to help resolve discrepancies in clinical history and questionnaire responses, rule out other sleep disorders, or evaluate efficacy of therapy. Measurements may include Multiple Sleep Latency Test, Maintenance of Wakefulness Test, or vigilance testing.	Strongly agree	60	70	100
		Agree with reservation	20	30	0
		Undecided	10	0	0
		Disagree	10	0	0
		Strongly disagree	0	0	0
31	The safety and efficacy of pharmacological treatment of residual EDS due to OSA should be clinically assessed and monitored	Strongly agree	60	100	100
		Agree with reservation			

Statement Number	Statement ^b	Response	Response Rate (%)		
			Round 1	Round 2	Round 3
32	periodically (frequency depending on clinical context) as part of a comprehensive continuum of care.	Undecided	30	0	0
		Disagree	10	0	0
		Strongly disagree	0	0	0
		Agree	0	0	0
		Strongly agree	90	90	90
		Agree with reservation	10	0	10
		Validated subjective and objective testing can complement the clinical assessment (Table 2).	0	10	0
			0	0	0
			0	0	0
				0	0

^aConsensus was considered to be achieved if 80% of respondents agreed or agreed with reservation.

^bFinal statements shown. CPAP = continuous positive airway pressure, EDS = excessive daytime sleepiness, ESS = Epworth Sleepiness Scale, IH = idiopathic hypersomnia, OA = oral appliance, OSA = obstructive sleep apnoea, PAP = positive airway pressure, PROMIS SRI=Patient-Reported Outcomes Measurement Information System Sleep-Related Impairment, QoL = quality of life.